Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy
- 18 August 2023
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 28 (11) , 1511-1519
Abstract
Background This prospective cohort study evaluated the feasibility of using endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) samples for comprehensive mutational analysis of cancer-related genes using microtissues. Methods Fifty patients with suspected pancreatic cancer presenting consecutively at the Kindai University Hospital between January 2018 and January 2019 were enrolled. Cancerous tissues from EUS-FNB were obtained from each tumor and subjected to histological examination and mutational analysis. The primary endpoint was the collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing. Clinical history and genetic variations between the disease control and progressive disease groups of patients on chemotherapy were evaluated as secondary endpoints. Results The collection rate of EUS-FNB specimens suitable for comprehensive cancer panels using deep sequencing was 93.6%. The cancer panel was sequenced for 25 patients with pancreatic cancer treated initially with systemic chemotherapy. Mutation in p53 and Smad4 were positively and negatively associated, respectively, with disease control at the initial evaluation. The median time to progression in 15 patients with p53 and without Smad4 mutations was 182.0 days; whereas, it was 92.5 days in other 10 patients; this difference was significant (p = 0.020). Conclusions Tissue samples from EUS-FNB were suitable for mutational analysis. Pancreatic cancers with p53 and without Smad4 mutations responded better to chemotherapy and had a better prognosis than those others.Keywords
Funding Information
- Clinical Pharmacology
- JSPS KAKENHI (21K07184)
- Smoking Research Foundation
This publication has 26 references indexed in Scilit:
- RNA sequencing distinguishes benign from malignant pancreatic lesions sampled by EUS-guided FNAGastrointestinal Endoscopy, 2016
- p53 in the DNA-Damage-Repair ProcessCold Spring Harbor Perspectives in Medicine, 2016
- Impact of p53 and PDGFR‐β Expression on Metastasis and Prognosis of Patients with Pancreatic CancerWorld Journal of Surgery, 2016
- Genomic analyses identify molecular subtypes of pancreatic cancerNature, 2016
- Molecular mechanisms of epithelial–mesenchymal transitionNature Reviews Molecular Cell Biology, 2014
- Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial–mesenchymal transition and chemoresistance in biliary tract cancerEuropean Journal of Cancer, 2013
- Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type IIMolecular and Cellular Biology, 2007
- Molecular Pathogenesis of Pancreatic CancerAnnual Review of Genomics and Human Genetics, 2003
- Overexpression of p53 Protein in Adenocarcinoma of the PancreasAmerican Journal of Clinical Pathology, 1994
- Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic diseaseGastrointestinal Endoscopy, 1992